Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 68 entries
Sorted by: Best Match Show Resources per page
Atrial fibrillation in ten cows.

The Canadian veterinary journal = La revue veterinaire canadienne

Brightling P, Townsend HG.
PMID: 17422324
Can Vet J. 1983 Nov;24(11):331-4.

An irregular cardiac rhythm was identified in ten adult cows during auscultation of the heart and was subsequently characterized as atrial fibrillation by electrocardiography. The occurrence of the arrhythmia was associated with primary, organic disease of the heart in...

Cite
Brightling P, Townsend HG. Atrial fibrillation in ten cows. Can Vet J. 1983;24(11):331-4
Brightling, P., & Townsend, H. G. (1983). Atrial fibrillation in ten cows. The Canadian veterinary journal = La revue veterinaire canadienne, 24(11), 331-4.
Brightling, P, and Townsend, H G. "Atrial fibrillation in ten cows." The Canadian veterinary journal = La revue veterinaire canadienne vol. 24,11 (1983): 331-4.
Brightling P, Townsend HG. Atrial fibrillation in ten cows. Can Vet J. 1983 Nov;24(11):331-4. PMID: 17422324; PMCID: PMC1790456.
Copy Download .nbib Format: NLM
The utility of the mannitol challenge in the assessment of chronic cough: a pilot study.

Cough (London, England)

Singapuri A, McKenna S, Brightling CE.
PMID: 19017380
Cough. 2008 Nov 18;4:10. doi: 10.1186/1745-9974-4-10.

There is a need for more objective outcome measures for chronic cough. In this pilot study we sought to investigate the utility of the mannitol challenge as a cough-provocation test in non-asthmatic chronic cough. We studied 16 healthy controls...

Cite
Singapuri A, McKenna S, Brightling CE. The utility of the mannitol challenge in the assessment of chronic cough: a pilot study. Cough. 2008;4:10doi: 10.1186/1745-9974-4-10.
Singapuri, A., McKenna, S., & Brightling, C. E. (2008). The utility of the mannitol challenge in the assessment of chronic cough: a pilot study. Cough (London, England), 410. https://doi.org/10.1186/1745-9974-4-10
Singapuri, Amisha, et al. "The utility of the mannitol challenge in the assessment of chronic cough: a pilot study." Cough (London, England) vol. 4 (2008): 10. doi: https://doi.org/10.1186/1745-9974-4-10
Singapuri A, McKenna S, Brightling CE. The utility of the mannitol challenge in the assessment of chronic cough: a pilot study. Cough. 2008 Nov 18;4:10. doi: 10.1186/1745-9974-4-10. PMID: 19017380; PMCID: PMC2596167.
Copy Download .nbib Format: NLM
Multi-scale computational models of the airways to unravel the pathophysiological mechanisms in asthma and chronic obstructive pulmonary disease (AirPROM).

Interface focus

Burrowes KS, De Backer J, Smallwood R, Sterk PJ, Gut I, Wirix-Speetjens R, Siddiqui S, Owers-Bradley J, Wild J, Maier D, Brightling C.
PMID: 24427517
Interface Focus. 2013 Apr 06;3(2):20120057. doi: 10.1098/rsfs.2012.0057.

THE RESPIRATORY SYSTEM COMPRISES SEVERAL SCALES OF BIOLOGICAL COMPLEXITY: the genes, cells and tissues that work in concert to generate resultant function. Malfunctions of the structure or function of components at any spatial scale can result in diseases, to...

Cite
Burrowes KS, De Backer J, Smallwood R, et al. Multi-scale computational models of the airways to unravel the pathophysiological mechanisms in asthma and chronic obstructive pulmonary disease (AirPROM). Interface Focus. 2013;3(2):20120057doi: 10.1098/rsfs.2012.0057.
Burrowes, K. S., De Backer, J., Smallwood, R., Sterk, P. J., Gut, I., Wirix-Speetjens, R., Siddiqui, S., Owers-Bradley, J., Wild, J., Maier, D., & Brightling, C. (2013). Multi-scale computational models of the airways to unravel the pathophysiological mechanisms in asthma and chronic obstructive pulmonary disease (AirPROM). Interface focus, 3(2), 20120057. https://doi.org/10.1098/rsfs.2012.0057
Burrowes, K S, et al. "Multi-scale computational models of the airways to unravel the pathophysiological mechanisms in asthma and chronic obstructive pulmonary disease (AirPROM)." Interface focus vol. 3,2 (2013): 20120057. doi: https://doi.org/10.1098/rsfs.2012.0057
Burrowes KS, De Backer J, Smallwood R, Sterk PJ, Gut I, Wirix-Speetjens R, Siddiqui S, Owers-Bradley J, Wild J, Maier D, Brightling C. Multi-scale computational models of the airways to unravel the pathophysiological mechanisms in asthma and chronic obstructive pulmonary disease (AirPROM). Interface Focus. 2013 Apr 06;3(2):20120057. doi: 10.1098/rsfs.2012.0057. PMID: 24427517; PMCID: PMC3638469.
Copy Download .nbib Format: NLM
Face mask sampling reveals antimicrobial resistance genes in exhaled aerosols from patients with chronic obstructive pulmonary disease and healthy volunteers.

BMJ open respiratory research

Kennedy M, Ramsheh MY, Williams CML, Auty J, Haldar K, Abdulwhhab M, Brightling CE, Barer MR.
PMID: 30271606
BMJ Open Respir Res. 2018 Sep 23;5(1):e000321. doi: 10.1136/bmjresp-2018-000321. eCollection 2018.

INTRODUCTION: The degree to which bacteria in the human respiratory tract are aerosolised by individuals is not established. Building on our experience sampling bacteria exhaled by individuals with pulmonary tuberculosis using face masks, we hypothesised that patients with conditions...

Cite
Kennedy M, Ramsheh MY, Williams CML, et al. Face mask sampling reveals antimicrobial resistance genes in exhaled aerosols from patients with chronic obstructive pulmonary disease and healthy volunteers. BMJ Open Respir Res. 2018;5(1):e000321doi: 10.1136/bmjresp-2018-000321.
Kennedy, M., Ramsheh, M. Y., Williams, C. M. L., Auty, J., Haldar, K., Abdulwhhab, M., Brightling, C. E., & Barer, M. R. (2018). Face mask sampling reveals antimicrobial resistance genes in exhaled aerosols from patients with chronic obstructive pulmonary disease and healthy volunteers. BMJ open respiratory research, 5(1), e000321. https://doi.org/10.1136/bmjresp-2018-000321
Kennedy, Matthew, et al. "Face mask sampling reveals antimicrobial resistance genes in exhaled aerosols from patients with chronic obstructive pulmonary disease and healthy volunteers." BMJ open respiratory research vol. 5,1 (2018): e000321. doi: https://doi.org/10.1136/bmjresp-2018-000321
Kennedy M, Ramsheh MY, Williams CML, Auty J, Haldar K, Abdulwhhab M, Brightling CE, Barer MR. Face mask sampling reveals antimicrobial resistance genes in exhaled aerosols from patients with chronic obstructive pulmonary disease and healthy volunteers. BMJ Open Respir Res. 2018 Sep 23;5(1):e000321. doi: 10.1136/bmjresp-2018-000321. eCollection 2018. PMID: 30271606; PMCID: PMC6157532.
Copy Download .nbib Format: NLM
Sputum Inflammatory Mediators Are Increased in Aspergillus fumigatus Culture-Positive Asthmatics.

Allergy, asthma & immunology research

Ghebre MA, Desai D, Singapuri A, Woods J, Rapley L, Cohen S, Herath A, Wardlaw AJ, Pashley CH, May R, Brightling CE.
PMID: 28102063
Allergy Asthma Immunol Res. 2017 Mar;9(2):177-181. doi: 10.4168/aair.2017.9.2.177.

Aspergillus fumigatus sensitization and culture in asthma are associated with disease severity and lung function impairment, but their relationship with airway inflammation is poorly understood. We investigated the profile of 24 sputum inflammatory mediators in A. fumigatus culture-positive or-negative...

Cite
Ghebre MA, Desai D, Singapuri A, et al. Sputum Inflammatory Mediators Are Increased in Aspergillus fumigatus Culture-Positive Asthmatics. Allergy Asthma Immunol Res. 2017;9(2):177-181doi: 10.4168/aair.2017.9.2.177.
Ghebre, M. A., Desai, D., Singapuri, A., Woods, J., Rapley, L., Cohen, S., Herath, A., Wardlaw, A. J., Pashley, C. H., May, R., & Brightling, C. E. (2017). Sputum Inflammatory Mediators Are Increased in Aspergillus fumigatus Culture-Positive Asthmatics. Allergy, asthma & immunology research, 9(2), 177-181. https://doi.org/10.4168/aair.2017.9.2.177
Ghebre, Michael A, et al. "Sputum Inflammatory Mediators Are Increased in Aspergillus fumigatus Culture-Positive Asthmatics." Allergy, asthma & immunology research vol. 9,2 (2017): 177-181. doi: https://doi.org/10.4168/aair.2017.9.2.177
Ghebre MA, Desai D, Singapuri A, Woods J, Rapley L, Cohen S, Herath A, Wardlaw AJ, Pashley CH, May R, Brightling CE. Sputum Inflammatory Mediators Are Increased in Aspergillus fumigatus Culture-Positive Asthmatics. Allergy Asthma Immunol Res. 2017 Mar;9(2):177-181. doi: 10.4168/aair.2017.9.2.177. PMID: 28102063; PMCID: PMC5266110.
Copy Download .nbib Format: NLM
Symptom Persistence Despite Improvement in Cardiopulmonary Health - Insights from longitudinal CMR, CPET and lung function testing post-COVID-19.

EClinicalMedicine

Cassar MP, Tunnicliffe EM, Petousi N, Lewandowski AJ, Xie C, Mahmod M, Samat AHA, Evans RA, Brightling CE, Ho LP, Piechnik SK, Talbot NP, Holdsworth D, Ferreira VM, Neubauer S, Raman B.
PMID: 34693230
EClinicalMedicine. 2021 Nov;41:101159. doi: 10.1016/j.eclinm.2021.101159. Epub 2021 Oct 20.

BACKGROUND: The longitudinal trajectories of cardiopulmonary abnormalities and symptoms following infection with coronavirus disease (COVID-19) are unclear. We sought to describe their natural history in previously hospitalised patients, compare this with controls, and assess the relationship between symptoms and...

Cite
Cassar MP, Tunnicliffe EM, Petousi N, et al. Symptom Persistence Despite Improvement in Cardiopulmonary Health - Insights from longitudinal CMR, CPET and lung function testing post-COVID-19. EClinicalMedicine. 2021;41:101159doi: 10.1016/j.eclinm.2021.101159.
Cassar, M. P., Tunnicliffe, E. M., Petousi, N., Lewandowski, A. J., Xie, C., Mahmod, M., Samat, A. H. A., Evans, R. A., Brightling, C. E., Ho, L. P., Piechnik, S. K., Talbot, N. P., Holdsworth, D., Ferreira, V. M., Neubauer, S., & Raman, B. (2021). Symptom Persistence Despite Improvement in Cardiopulmonary Health - Insights from longitudinal CMR, CPET and lung function testing post-COVID-19. EClinicalMedicine, 41101159. https://doi.org/10.1016/j.eclinm.2021.101159
Cassar, Mark Philip, et al. "Symptom Persistence Despite Improvement in Cardiopulmonary Health - Insights from longitudinal CMR, CPET and lung function testing post-COVID-19." EClinicalMedicine vol. 41 (2021): 101159. doi: https://doi.org/10.1016/j.eclinm.2021.101159
Cassar MP, Tunnicliffe EM, Petousi N, Lewandowski AJ, Xie C, Mahmod M, Samat AHA, Evans RA, Brightling CE, Ho LP, Piechnik SK, Talbot NP, Holdsworth D, Ferreira VM, Neubauer S, Raman B. Symptom Persistence Despite Improvement in Cardiopulmonary Health - Insights from longitudinal CMR, CPET and lung function testing post-COVID-19. EClinicalMedicine. 2021 Nov;41:101159. doi: 10.1016/j.eclinm.2021.101159. Epub 2021 Oct 20. PMID: 34693230; PMCID: PMC8527025.
Copy Download .nbib Format: NLM
Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study.

The Lancet. Respiratory medicine

Evans RA, McAuley H, Harrison EM, Shikotra A, Singapuri A, Sereno M, Elneima O, Docherty AB, Lone NI, Leavy OC, Daines L, Baillie JK, Brown JS, Chalder T, De Soyza A, Diar Bakerly N, Easom N, Geddes JR, Greening NJ, Hart N, Heaney LG, Heller S, Howard L, Hurst JR, Jacob J, Jenkins RG, Jolley C, Kerr S, Kon OM, Lewis K, Lord JM, McCann GP, Neubauer S, Openshaw PJM, Parekh D, Pfeffer P, Rahman NM, Raman B, Richardson M, Rowland M, Semple MG, Shah AM, Singh SJ, Sheikh A, Thomas D, Toshner M, Chalmers JD, Ho LP, Horsley A, Marks M, Poinasamy K, Wain LV, Brightling CE.
PMID: 34627560
Lancet Respir Med. 2021 Nov;9(11):1275-1287. doi: 10.1016/S2213-2600(21)00383-0. Epub 2021 Oct 07.

BACKGROUND: The impact of COVID-19 on physical and mental health and employment after hospitalisation with acute disease is not well understood. The aim of this study was to determine the effects of COVID-19-related hospitalisation on health and employment, to...

Cite
Evans RA, McAuley H, Harrison EM, et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir Med. 2021;9(11):1275-1287doi: 10.1016/S2213-2600(21)00383-0.
Evans, R. A., McAuley, H., Harrison, E. M., Shikotra, A., Singapuri, A., Sereno, M., Elneima, O., Docherty, A. B., Lone, N. I., Leavy, O. C., Daines, L., Baillie, J. K., Brown, J. S., Chalder, T., De Soyza, A., Diar Bakerly, N., Easom, N., Geddes, J. R., Greening, N. J., Hart, N., Heaney, L. G., Heller, S., Howard, L., Hurst, J. R., Jacob, J., Jenkins, R. G., Jolley, C., Kerr, S., Kon, O. M., Lewis, K., Lord, J. M., McCann, G. P., Neubauer, S., Openshaw, P. J. M., Parekh, D., Pfeffer, P., Rahman, N. M., Raman, B., Richardson, M., Rowland, M., Semple, M. G., Shah, A. M., Singh, S. J., Sheikh, A., Thomas, D., Toshner, M., Chalmers, J. D., Ho, L. P., Horsley, A., Marks, M., Poinasamy, K., Wain, L. V., Brightling, C. E. (2021). Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. The Lancet. Respiratory medicine, 9(11), 1275-1287. https://doi.org/10.1016/S2213-2600(21)00383-0
Evans, Rachael A, et al. "Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study." The Lancet. Respiratory medicine vol. 9,11 (2021): 1275-1287. doi: https://doi.org/10.1016/S2213-2600(21)00383-0
Evans RA, McAuley H, Harrison EM, Shikotra A, Singapuri A, Sereno M, Elneima O, Docherty AB, Lone NI, Leavy OC, Daines L, Baillie JK, Brown JS, Chalder T, De Soyza A, Diar Bakerly N, Easom N, Geddes JR, Greening NJ, Hart N, Heaney LG, Heller S, Howard L, Hurst JR, Jacob J, Jenkins RG, Jolley C, Kerr S, Kon OM, Lewis K, Lord JM, McCann GP, Neubauer S, Openshaw PJM, Parekh D, Pfeffer P, Rahman NM, Raman B, Richardson M, Rowland M, Semple MG, Shah AM, Singh SJ, Sheikh A, Thomas D, Toshner M, Chalmers JD, Ho LP, Horsley A, Marks M, Poinasamy K, Wain LV, Brightling CE. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir Med. 2021 Nov;9(11):1275-1287. doi: 10.1016/S2213-2600(21)00383-0. Epub 2021 Oct 07. PMID: 34627560; PMCID: PMC8497028.
Copy Download .nbib Format: NLM
The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease.

The Lancet. Respiratory medicine

Adeloye D, Elneima O, Daines L, Poinasamy K, Quint JK, Walker S, Brightling CE, Siddiqui S, Hurst JR, Chalmers JD, Pfeffer PE, Novotny P, Drake TM, Heaney LG, Rudan I, Sheikh A, De Soyza A.
PMID: 34416191
Lancet Respir Med. 2021 Dec;9(12):1467-1478. doi: 10.1016/S2213-2600(21)00286-1. Epub 2021 Aug 17.

Persistent ill health after acute COVID-19-referred to as long COVID, the post-acute COVID-19 syndrome, or the post-COVID-19 condition-has emerged as a major concern. We undertook an international consensus exercise to identify research priorities with the aim of understanding the...

Cite
Adeloye D, Elneima O, Daines L, et al. The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease. Lancet Respir Med. 2021;9(12):1467-1478doi: 10.1016/S2213-2600(21)00286-1.
Adeloye, D., Elneima, O., Daines, L., Poinasamy, K., Quint, J. K., Walker, S., Brightling, C. E., Siddiqui, S., Hurst, J. R., Chalmers, J. D., Pfeffer, P. E., Novotny, P., Drake, T. M., Heaney, L. G., Rudan, I., Sheikh, A., De Soyza, A. (2021). The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease. The Lancet. Respiratory medicine, 9(12), 1467-1478. https://doi.org/10.1016/S2213-2600(21)00286-1
Adeloye, Davies, et al. "The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease." The Lancet. Respiratory medicine vol. 9,12 (2021): 1467-1478. doi: https://doi.org/10.1016/S2213-2600(21)00286-1
Adeloye D, Elneima O, Daines L, Poinasamy K, Quint JK, Walker S, Brightling CE, Siddiqui S, Hurst JR, Chalmers JD, Pfeffer PE, Novotny P, Drake TM, Heaney LG, Rudan I, Sheikh A, De Soyza A. The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease. Lancet Respir Med. 2021 Dec;9(12):1467-1478. doi: 10.1016/S2213-2600(21)00286-1. Epub 2021 Aug 17. PMID: 34416191; PMCID: PMC8372501.
Copy Download .nbib Format: NLM
Volatile organic compounds in a headspace sampling system and asthmatics sputum samples.

Journal of breath research

Peltrini R, Cordell R, Ibrahim W, Wilde M, Salman D, Singapuri A, Hargadon B, Brightling CE, Thomas CLP, Monks P, Siddiqui S.
PMID: 33227714
J Breath Res. 2020 Nov 23; doi: 10.1088/1752-7163/abcd2a. Epub 2020 Nov 23.

No abstract available.

Cite
Peltrini R, Cordell R, Ibrahim W, et al. Volatile organic compounds in a headspace sampling system and asthmatics sputum samples. J Breath Res. 2020;doi: 10.1088/1752-7163/abcd2a.
Peltrini, R., Cordell, R., Ibrahim, W., Wilde, M., Salman, D., Singapuri, A., Hargadon, B., Brightling, C. E., Thomas, C. L. P., Monks, P., & Siddiqui, S. (2020). Volatile organic compounds in a headspace sampling system and asthmatics sputum samples. Journal of breath research, . https://doi.org/10.1088/1752-7163/abcd2a
Peltrini, Rosa, et al. "Volatile organic compounds in a headspace sampling system and asthmatics sputum samples." Journal of breath research vol. (2020). doi: https://doi.org/10.1088/1752-7163/abcd2a
Peltrini R, Cordell R, Ibrahim W, Wilde M, Salman D, Singapuri A, Hargadon B, Brightling CE, Thomas CLP, Monks P, Siddiqui S. Volatile organic compounds in a headspace sampling system and asthmatics sputum samples. J Breath Res. 2020 Nov 23; doi: 10.1088/1752-7163/abcd2a. Epub 2020 Nov 23. PMID: 33227714.
Copy Download .nbib Format: NLM
Global Initiative for Asthma (GINA) Strategy 2021 - Executive summary and rationale for key changes.

The European respiratory journal

Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, Cruz AA, Duijts L, Drazen JM, FitzGerald JM, Fleming LJ, Inoue H, Ko FW, Krishnan JA, Levy ML, Lin J, Mortimer K, Pitrez PM, Sheikh A, Yorgancioglu AA, Boulet LP.
PMID: 34667060
Eur Respir J. 2021 Oct 19; doi: 10.1183/13993003.02730-2021. Epub 2021 Oct 19.

The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually updated evidence-based strategy for asthma management and prevention, which can be adapted for local circumstances (e.g., medication availability). This article summarizes key recommendations from GINA 2021,...

Cite
Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma (GINA) Strategy 2021 - Executive summary and rationale for key changes. Eur Respir J. 2021;doi: 10.1183/13993003.02730-2021.
Reddel, H. K., Bacharier, L. B., Bateman, E. D., Brightling, C. E., Brusselle, G. G., Buhl, R., Cruz, A. A., Duijts, L., Drazen, J. M., FitzGerald, J. M., Fleming, L. J., Inoue, H., Ko, F. W., Krishnan, J. A., Levy, M. L., Lin, J., Mortimer, K., Pitrez, P. M., Sheikh, A., Yorgancioglu, A. A., & Boulet, L. P. (2021). Global Initiative for Asthma (GINA) Strategy 2021 - Executive summary and rationale for key changes. The European respiratory journal, . https://doi.org/10.1183/13993003.02730-2021
Reddel, Helen K, et al. "Global Initiative for Asthma (GINA) Strategy 2021 - Executive summary and rationale for key changes." The European respiratory journal vol. (2021). doi: https://doi.org/10.1183/13993003.02730-2021
Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, Cruz AA, Duijts L, Drazen JM, FitzGerald JM, Fleming LJ, Inoue H, Ko FW, Krishnan JA, Levy ML, Lin J, Mortimer K, Pitrez PM, Sheikh A, Yorgancioglu AA, Boulet LP. Global Initiative for Asthma (GINA) Strategy 2021 - Executive summary and rationale for key changes. Eur Respir J. 2021 Oct 19; doi: 10.1183/13993003.02730-2021. Epub 2021 Oct 19. PMID: 34667060.
Copy Download .nbib Format: NLM
Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial.

The Lancet. Respiratory medicine

Diver S, Khalfaoui L, Emson C, Wenzel SE, Menzies-Gow A, Wechsler ME, Johnston J, Molfino N, Parnes JR, Megally A, Colice G, Brightling CE.
PMID: 34256031
Lancet Respir Med. 2021 Nov;9(11):1299-1312. doi: 10.1016/S2213-2600(21)00226-5. Epub 2021 Jul 10.

BACKGROUND: Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin (TSLP), an epithelial cell-derived cytokine. In phase 2b and 3 studies, tezepelumab significantly reduced exacerbations versus placebo in patients with severe uncontrolled asthma, irrespective...

Cite
Diver S, Khalfaoui L, Emson C, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299-1312doi: 10.1016/S2213-2600(21)00226-5.
Diver, S., Khalfaoui, L., Emson, C., Wenzel, S. E., Menzies-Gow, A., Wechsler, M. E., Johnston, J., Molfino, N., Parnes, J. R., Megally, A., Colice, G., Brightling, C. E. (2021). Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet. Respiratory medicine, 9(11), 1299-1312. https://doi.org/10.1016/S2213-2600(21)00226-5
Diver, Sarah, et al. "Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial." The Lancet. Respiratory medicine vol. 9,11 (2021): 1299-1312. doi: https://doi.org/10.1016/S2213-2600(21)00226-5
Diver S, Khalfaoui L, Emson C, Wenzel SE, Menzies-Gow A, Wechsler ME, Johnston J, Molfino N, Parnes JR, Megally A, Colice G, Brightling CE. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021 Nov;9(11):1299-1312. doi: 10.1016/S2213-2600(21)00226-5. Epub 2021 Jul 10. PMID: 34256031.
Copy Download .nbib Format: NLM
Fatty airways: a source of good and bad fats?.

The European respiratory journal

Brightling CE, Tobin AB, Milligan G.
PMID: 31831675
Eur Respir J. 2019 Dec 12;54(6). doi: 10.1183/13993003.02060-2019. Print 2019 Dec.

No abstract available.

Cite
Brightling CE, Tobin AB, Milligan G. Fatty airways: a source of good and bad fats?. Eur Respir J. 2019;54(6)doi: 10.1183/13993003.02060-2019.
Brightling, C. E., Tobin, A. B., & Milligan, G. (2019). Fatty airways: a source of good and bad fats?. The European respiratory journal, 54(6), . https://doi.org/10.1183/13993003.02060-2019
Brightling, Christopher E, et al. "Fatty airways: a source of good and bad fats?." The European respiratory journal vol. 54,6 (2019). doi: https://doi.org/10.1183/13993003.02060-2019
Brightling CE, Tobin AB, Milligan G. Fatty airways: a source of good and bad fats?. Eur Respir J. 2019 Dec 12;54(6). doi: 10.1183/13993003.02060-2019. Print 2019 Dec. PMID: 31831675.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 68 entries